tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Hartaj Singh, 153 are a BUY (92.73%), 2 are a SELL (1.21%), 10 are a HOLD (6.06%).
Analyst Hartaj Singh, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 42.1% that have a potential upside of 40.37% achieved within 235 days.
Hartaj Singh’s has documented 321 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 10-Jan-2025.
Analyst best performing recommendations are on ONCT (ONCTERNAL THERAPEUTICS).
The best stock recommendation documented was for MRNA (MODERNA) at 4/15/2020. The price target of $43 was fulfilled within 2 days with a profit of $5.75 (15.44%) receiving and performance score of 77.18.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$22.5 (12.33%)
4 years 3 months 4 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold
$173
$-9.5 (-5.21%)
$156
4 years 3 months 6 days ago
(03-May-2021)
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
$190
4 years 3 months 14 days ago
(26-Apr-2021)
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
$166
$-16.5 (-9.04%)
$175
4 years 6 months 5 days ago
(04-Feb-2021)
23/23 (100%)
$10.41 (6.69%)
828
Buy
$155
4 years 7 months 2 days ago
(07-Jan-2021)
7/7 (100%)
$36.79 (31.12%)
395
What Year was the first public recommendation made by Hartaj Singh?
